Grant: Engage Grants Program
University of Alberta
$25,000.00
Validation of antimicrobial drug target selection using X-ray crystallographic methods
FY 2010-11
Summary
Indel Therapeutics Inc. is a Vancouver-headquartered antibiotic drug discovery company aiming to develop a pipeline of anti-microbials using its proprietary antibiobiotic target selection platform. Indel has embarked upon a collaborative venture with the laboratory of Dr. Michael James at the University of Alberta to experimentally validate the Indel platform. The James laboratory specializes in determining the X-ray crystal structures of proteins and protein-nucleic acid complexes and is a world leader in the field. The molecular structure of high-priority targets identified by the Indel process will be determined. This knowledge will enable virtual screening to identify potential inhibitors of the target protein. Subsequent molecular structures of target-inhibitor complexes will reveal whether Indel targeting predictions are correlated with what is observed experimentally. Going forward, the structural insights will allow crystallographers to rationally guide the improvement of the inhibitor to increase its potency and specificity. Additionally, the development of a robust assay of a target's activity will enable Indel to develop a high throughput screen to test inhibitors that emerge from its medicinal chemistry arm.
Program
Engage Grants Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
411306-2010
Name nom
James, Michael
Department département
Biochemistry
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
Validation of antimicrobial drug target selection using X-ray crystallographic methods
Keyword
NSERC
Application summary
Indel Therapeutics Inc. is a Vancouver-headquartered antibiotic drug discovery company aiming to develop a pipeline of anti-microbials using its proprietary antibiobiotic target selection platform. Indel has embarked upon a collaborative venture with the laboratory of Dr. Michael James at the University of Alberta to experimentally validate the Indel platform. The James laboratory specializes in determining the X-ray crystal structures of proteins and protein-nucleic acid complexes and is a world leader in the field. The molecular structure of high-priority targets identified by the Indel process will be determined. This knowledge will enable virtual screening to identify potential inhibitors of the target protein. Subsequent molecular structures of target-inhibitor complexes will reveal whether Indel targeting predictions are correlated with what is observed experimentally. Going forward, the structural insights will allow crystallographers to rationally guide the improvement of the inhibitor to increase its potency and specificity. Additionally, the development of a robust assay of a target's activity will enable Indel to develop a high throughput screen to test inhibitors that emerge from its medicinal chemistry arm.